

Please replace the paragraph on page 24, lines 5-8 as follows:

A solution of ramoplanin at 10 mg/ml of activity was prepared in NaCl 0.9% (w/vol).

B12

The solution was sterilized by filtration with 0.22 μ m pore-size filters.

IN THE CLAIMS

Please amend the claims as follows.

--7. (Twice Amended) A formulation according to claim 1 wherein the fat emulsion product employed for the preparation of said formulation comprises a composition selected from those reported in the following tables:

	Fat emulsion product 1	Fat emulsion product 2	Fat emulsion product 3
Soybean oil (w/vol)	10%	20%	5%
Safflower oil (w/vol)	--	--	5%
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.25%	2.25%	2.5%
Fatty acids composition of vegetable oils (w/vol)			
Linoleic acid	50%	50%	65.8%
Oleic acid	26%	26%	17.7%
Palmitic acid	10%	10%	8.8%
Linolenic acid	9%	9%	4.2%
Stearic acid	3.5%	3.5%	3.4%
Osmolarity (mOsm/L)	260	268	276
Approximate pH	8	8	8
Fat particle size (μ m)	0.5	0.5	0.4
Caloric value (cal/ml)	1.1	2.0	1.1
Size (ml)	50, 100	50, 100	25, 50

B13
conclude

	250 or	250 or	100, 200
	500	500	Or 500
	Fat emulsion product 4	Fat emulsion product 5	Fat emulsion product 6
Soybean oil (w/vol)	10%	10%	20%
Safflower oil (w/vol)	10%	--	--
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.5%	2.5%	2.5%
Fatty acids composition of vegetable oil (w/vol)			
Linoleic acid	65.8%	54.5%	54.5%
Oleic acid	17.7%	22.4%	22.4%
Palmitic acid	8.8%	10.5%	10.5%
Linolenic acid	4.2%	8.3%	8.3%
Stearic acid	3.4%	4.2%	4.2%
Osmolarity (mOsm/L)	258	284	292
Approximate pH	8.3	8.3	8.3
Fat particle size (μm)	0.4	0.4	0.4
Caloric value (cal/ml)	2.0	1.1	2.0
Size (ml)	25, 50	100, 200	200 or
	200 or	Or 500	550
	500		

and water for injection is from quite small to 100%.

B14
pass

14. (Twice Amended) A formulation according to claim 1 for treatment of infections caused by microorganisms whose proliferation is inhibited, reduced, alleviated, or arrested in the presence of ramoplanin or an antibiotic of the ramoplanin family.

B11
agrade
15. (Twice Amended) A method of treating Gram positive infections, comprising administering the formulation according to claim 1 to a patient in need thereof.--

Please add the following claims.

B15
--36. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_2 .

37. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_2' .

38. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_1 .

39. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_1' .

40. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_3 .

41. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor A_3' .

qds
42. (New) The method according to Claim 15, wherein the Gram positive infection is at least one member selected from the group consisting of bacteremia, endocarditis, and pneumonia.--